Canada · Delayed Price · Currency is CAD COSCIENS Biopharma Company Description
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally.
It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries.
It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland.
The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta.
The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024.
COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
| Country | Canada |
| Founded | 1990 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Peter Puccetti |
Contact Details
Address: 22 Adelaide Street West Toronto, ON M5H 4E3 Canada | |
| Phone | 843 900 3223 |
| Website | cosciensbio.com |
Stock Details
| Ticker Symbol | CSCI |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA22112H1010 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Harry Puccetti CFA | Interim Chief Executive Officer and Independent Chairman |
| Giuliano La Fratta | Senior Vice President of Finance and Chief Financial Officer |
| Dr. Michael Teifel Ph.D. | Senior Vice President of Non-Clinical Development and Chief Scientific Officer |
| Dr. Matthias Gerlach | Senior Vice President and MD of Zentaris IVF GmbH |
| Michel Regnier P. Eng. | Senior Vice President and MD of Edmonton |
| Dr. Nicola Ammer M.D. | Senior Vice President and Chief Medical Officer |